Items where authors include "Hurst, CD"

Article

Pettitt, GA, Hurst, CD, Khan, Z et al. (7 more authors) (2023) Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro. Journal of Pathology, 259 (2). pp. 220-232. ISSN 0022-3417

Warrick, JI, Knowles, MA orcid.org/0000-0002-9363-8657, Hurst, CD et al. (9 more authors) (2022) A transcriptional network of cell cycle dysregulation in noninvasive papillary urothelial carcinoma. Scientific Reports, 12 (1). 16538. ISSN 2045-2322

Marzouka, N-A-D, Eriksson, P, Bernardo, C et al. (5 more authors) (2022) The Lund Molecular Taxonomy Applied to Non–Muscle-Invasive Urothelial Carcinoma. The Journal of Molecular Diagnostics, 24 (9). pp. 992-1008. ISSN 1525-1578

Hurst, CD orcid.org/0000-0001-7719-1325 and Knowles, MA orcid.org/0000-0002-9363-8657 (2022) Mutational landscape of non-muscle-invasive bladder cancer. Urologic Oncology, 40 (7). pp. 295-303. ISSN 1078-1439

Hurst, CD, Cheng, G, Platt, FM et al. (7 more authors) (2022) Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling. The Journal of Pathology: Clinical Research, 8 (3). pp. 279-293. ISSN 2056-4538

Hurst, CD, Cheng, G, Platt, FM et al. (16 more authors) (2021) Stage-stratified molecular profiling of non-muscle-invasive bladder cancer provides improved biological, clinical and therapeutic insights. Cell Reports Medicine, 2 (12). 100472. ISSN 2666-3791

Lindskrog, SV, Prip, F, Lamy, P et al. (44 more authors) (2021) An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 12 (1). 2301. ISSN 2041-1723

Burns, JE, Hurst, CD, Knowles, MA orcid.org/0000-0002-9363-8657 et al. (2 more authors) (2021) The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets. Cancer Science. cas.15047. ISSN 1347-9032

Pritchard, JJG, Hamilton, G, Hurst, CD et al. (6 more authors) (2020) Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Urologic Oncology: Seminars and Original Investigations, 38 (9). 737.e1-737.e10. ISSN 1078-1439

Di Martino, E, Alder, O orcid.org/0000-0002-7975-9727, Hurst, CD orcid.org/0000-0001-7719-1325 et al. (1 more author) (2019) ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer. Scientific Reports, 9. ARTN: 5740. ISSN 2045-2322

Hurst, CD and Knowles, MA orcid.org/0000-0002-9363-8657 (2018) Bladder cancer: Multi-omic profiling refines the molecular view. Nature Reviews Clinical Oncology, 15. pp. 203-204. ISSN 1759-4774

Hurst, CD orcid.org/0000-0001-7719-1325, Alder, O orcid.org/0000-0002-7975-9727, Platt, FM et al. (15 more authors) (2017) Genomic Subtypes of Non-Invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Cancer Cell, 32 (5). pp. 701-715. ISSN 1535-6108

Ross, RL, McPherson, HR, Kettlewell, L et al. (4 more authors) (2016) PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer, 16. 553. ISSN 1471-2407

Pouessel, D, Neuzillet, Y, Mertens, LS et al. (35 more authors) (2016) Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment. Annals of Oncology, 27 (7). pp. 1311-1316. ISSN 0923-7534

De Faveri, LE, Hurst, CD, Roulson, J et al. (4 more authors) (2015) Polycomb repressor complex 1 member, BMI1 contributes to urothelial tumorigenesis through p16-independent mechanisms. Translational Oncology, 8 (5). pp. 387-399. ISSN 1944-7124

Burghel, GJ, Hurst, CD, Watson, CM et al. (4 more authors) (2015) Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms. BioMed Research International, 2015. 478017. ISSN 2314-6133

Stoehr, R, Taubert, H, Zinnall, U et al. (8 more authors) (2015) Frequency of TERT promoter mutations in prostate cancer. Pathobiology, 82 (2). pp. 53-57. ISSN 1015-2008

Knowles, MA and Hurst, CD (2014) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature Reviews Cancer, 15 (1). 25 - 41. ISSN 1474-175X

Taylor, CF, Platt, FM, Hurst, CD orcid.org/0000-0001-7719-1325 et al. (2 more authors) (2014) Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Human Molecular Genetics, 23 (8). pp. 1964-1974. ISSN 0964-6906

Hurst, CD and Knowles, MA (2014) Molecular subtyping of invasive bladder cancer: time to divide and rule? Cancer Cell, 25 (2). 135 - 136. ISSN 1535-6108

De Faveri, LE, Hurst, CD orcid.org/0000-0001-7719-1325, Platt, FM et al. (5 more authors) (2013) Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer. British Journal of Cancer, 108 (6). pp. 1368-1377. ISSN 0007-0920